Atrioventricular node reentry: intravenous verapamil as a method of defining multiple electrophysiologic types

Clinical significance of wide QRS complexes at the termination of paroxysmal supraventricular tachycardias

BACKGROUND

A wide QRS complex is not a rare electrocardiographic phenomenon at the termination of paroxysmal supraventricular tachycardia (PSVT), but no plausible underlying mechanism has yet been proposed. The purpose of the present study was to elucidate the frequency and the underlying mechanism of the wide QRS complexes at the termination of PSVT.

METHODS

We retrospectively reviewed 305 electrocardiograms (ECGs) from 100 patients, on which PSVT termination was recorded. The frequency of the wide QRS complexes was analyzed in 181 ECGs to avoid duplication, because there were 124 ECGs obtained from the same patients with same methods. The 181 ECGs were divided by morphology into three groups: Type A, termination with wide QRS complex without pause; Type B, wide QRS complex following initial pause after termination; Type C, wide QRS complex following the first narrow QRS after termination.

RESULTS

The wide QRS complex was recorded in 81/181 (44.8%) ECGs (Type A; 3/81 (3.7%), Type B; 44/81 (54.3%), Type C; 62/81 (55.6%) ) and its frequency was not dependent on the mechanism of PSVT. It was more frequently observed after a long pause, and was frequently induced by procedures that increase vagal tone, such as intravenous adenosine 5'-triphosphate administration (16/22: 72.7%) and vagal stimulation maneuvers (16/32: 50%). There were a total of 41 wide QRS complexes (44.6%) which had a preceding sinus P wave, out of a total of 92 wide QRS complexes in all three types. These 41 wide QRS complexes included 30/44 (68.2%) Type B wide QRS, and 11 (24.4%) Type C wide QRS complexes.

CONCLUSION

The aberrant conduction or escaped ventricular contraction was suggested to be the underlying mechanism of the majority of wide QRS complexes and ventricular premature contraction is less frequent.

Atrioventricular nodal reentrant tachycardia with atrioventricular block

Atrioventricular block (AVB) during atrioventricular nodal reentrant tachycardia (AVNRT) has been well documented, although it is not a common phenomenon. The mechanism for the initiation and resolution of AVB during AVNRT have been postulated. However, the site of AVB and its implication on the reentrant circuit in AVNRT is not clear. We illustrate two examples of AVNRT with AVB and offer further clarification on the site and mechanism of AVB.

Acute management of paroxysmal atrioventricular junctional reentrant supraventricular tachycardia: pharmacologic strategies

A vast array of effective antiarrhythmic agents offers the attending physician attractive options for termination of PJRT. Calcium channel blockers, adenosine compounds, amjaline, and the newer drugs flecainide and propafenone offer an efficacy rate of more than 80% for acute termination of PJRT. Choice should be based on the patient's clinical characteristics including any underlying cardiac or noncardiac pathologic conditions, hemodynamic status, and current medications. Drugs with a very short half-life (adenosine compounds) offer the possibility of repeated administration at increasing dosages or of subsequent administration of a second antiarrhythmic drug without fear of increased adverse effects or drug interactions. Drugs with a long half-life, such as calcium channel blockers, flecainide, and propafenone, have the potential advantage of preventing an immediate recurrence of the arrhythmia. Adenosine compounds are the fastest acting drugs, resulting in termination of PJRT in less than 30 seconds. The cardiac side effects of all antiarrhythmic drugs represent an exaggeration of their intrinsic electrophysiologic and hemodynamic effects. Thus hemodynamic decompensation and bradyarrhythmias resulting from sinus nodal, AV nodal, or infranodal dysfunction are of major concern. Side effects of adenosine compounds are extremely common but very short lasting. Verapamil is both highly effective and safe except in very special circumstances. Guidelines for therapy of PJRT in specific groups of patients are provided.

Failure of episodic high-dose oral verapamil therapy to convert supraventricular tachycardia: a study of plasma verapamil levels and gastric motility

The practicality of administering large oral doses of verapamil tablets to terminate supraventricular tachycardia (SVT) was investigated in 10 patients. A pilot study in four patients showed that unexpectedly low plasma levels (less than 40 ng/ml) were obtained 60 minutes after administering 160 mg or 240 mg of verapamil during SVT. Nuclear studies in the six other patients showed that fractional liquid gastric emptying times (T) were significantly prolonged in SVT compared to sinus rhythm (SR), p less than 0.05 from T 1/3 onward. Further verapamil absorption studies (200 to 360 mg) performed during SVT and SR in five of six patients showed that peak verapamil levels in four patients in SVT were 23% to 71% lower than in sinus rhythm, where they had peaked at greater than 250 ng/ml 60 minutes post verapamil ingestion, and areas under the plasma concentration time curves were 26% to 100% (mean 67%) less in SVT than in SR for all five patients. SVT was terminated by verapamil in one patient after 40 minutes and the rate of SVT was slowed after 90 minutes in two other patients. Thus plasma verapamil levels are considerably reduced during SVT as compared to SR, and changes in gastric emptying are likely a contributing cause. Since SVT was converted to sinus rhythm in only 1 of 10 patients within 1 hour, large oral doses of verapamil tablets appear unsatisfactory for the episodic treatment of SVT.

Characteristics of ventriculoatrial conduction in patients with enhanced atrioventricular nodal conduction

To study the characteristics of the ventriculoatrial conduction system in patients capable of rapid antegrade atrioventricular conduction, electrophysiologic studies were performed in 23 subjects capable of 1:1 atrioventricular conduction at atrial cycle lengths less than or equal to 300 ms (Group I), and in 23 subjects with normal 1:1 atrioventricular conduction (Group II). During ventricular pacing, ventriculoatrial block at all cycle lengths was seen in 5/23 (22%) in Group I and in 7/23 (30%) in Group II patients (p = NS). In the remainder, the minimum ventricular pacing cycle length maintaining 1:1 ventriculoatrial conduction was 359 +/- 85 ms in Group I, compared to 444 +/- 118 ms in Group II (p less than .02). Both flat and exponential VA conduction interval curves, drawn as a function of pacing cycle length, were observed in both groups. Discontinuous ventriculoatrial conduction curves were seen in 5/18 (28%) Group I and 1/16 (6%) Group II patients (p = NS). In conclusion, retrograde ventriculoatrial conduction, when present in patients capable of rapid 1:1 atrioventricular conduction, is maintained at shorter cycle lengths than in patients with normal atrioventricular conduction. Quantitative, rather than qualitative, differences distinguish the two groups.

Effect of verapamil on retrograde conduction in atrioventricular nodal reentrant tachycardia

Using His bundle electrograms, incremental ventricular pacing and the ventricular extrastimulus (V2) technique, the effects of intravenous verapamil, 0.2 mg/kg, on retrograde atrioventricular (AV) nodal conduction during ventricular pacing, premature ventricular stimulation (H2A2 interval) and paroxysmal supraventricular tachycardia (SVT) (H-Ae interval) were evaluated in 11 patients with AV nodal reentrant tachycardia. During the control study, SVT could be induced in all 11 patients. After verapamil administration, SVT or atrial echo beats could be induced in 5 patients. Verapamil produced ventriculoatrial (VA) block at a longer cycle length than that during the control study in 10 of 11 patients (295 +/- 27 vs 352 +/- 40 ms, p less than 0.01), but prolonged H2A2 interval in only 5 of 11 patients (37 +/- 6 vs 60 +/- 31 ms, p less than 0.05). In all 5 patients with persistence of inducible SVT or atrial echo beats after verapamil treatment, the H-Ae interval remained unchanged even though in 4 of these 5 patients VA conduction time or H2A2 interval was prolonged. Correlation between the paced cycle length which induced VA block, the shortest V1H2 interval achieved during premature ventricular stimulation and the cycle length of SVT revealed that in all instances in which verapamil induced VA block at a longer cycle length than in controls but did not prolong H2A2 or H-Ae interval, the shortest V1H2 interval and the cycle length of SVT (H-H interval) were significantly longer than the ventricular paced cycle length which produced VA block.(ABSTRACT TRUNCATED AT 250 WORDS)

Paroxysmal supraventricular tachycardia with Wenckebach block: evidence for reentry within the upper portion of the atrioventricular node

Paroxysmal supraventricular tachycardia with Wenckebach block is an uncommon electrocardiographic finding. Electrophysiologic studies performed in a patient who exhibited this phenomenon indicated that the tachycardia was not caused by either sinus node or intraatrial reentry or abnormal automaticity. The tachycardia cycle length decreased after atropine administration and increased in response to propranolol. Administration of either adenosine (75 to 112.5 micrograms/kg) or verapamil (10 mg) terminated individual episodes of tachycardia. After verapamil and when atrial extrastimuli were introduced, dissociation of atrial activity from His-ventricular activity could be observed even though atrioventricular (AV) nodal block with a clear Wenckebach periodicity could also occur. These findings suggest that paroxysmal supraventricular tachycardia may be produced by reentry located solely within the upper portion of the AV node.

Verapamil effects in AV node reentry tachycardia with intermittent supra-Hisian AV block

The electrophysiologic details of two patients with atrioventricular (AV) node reentry tachycardia with intermittent 2:1 supra-Hisian block are presented. Both patients had clear evidence for atrial arrhythmias as well, emphasizing the need for a careful diagnostic analysis. Evidence supporting a diagnosis of AV node reentry tachycardia included: (1) short ventriculoatrial (VA) coupling intervals, (2) normal retrograde sequence of atrial activation, (3) dependence on critical AV node conduction times for initiation of tachycardia by atrial pacing, (4) ability to pace and capture the atria or ventricles without interrupting the tachycardia, and (5) fixed VA coupling intervals despite changes in tachycardia cycle length. Ten milligrams of verapamil was administered during sustained supraventricular tachycardia with 1:1 AV conduction, but despite prompt termination of tachycardia in both cases, 2:1 AV block was not induced. Atrial echoes could still be induced after verapamil, and diagnostic features (3) and (5) were particularly evident after the drug. Further analysis confirmed that verapamil did not have any observable effects on the likely site for supra-Hisian block--that is, the "final common pathway" of the AV node. This would support a contention that verapamil may have a selective effect on tissues within the confines of the AV node.